Article info

Download PDFPDF
Original research
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab

Authors

  1. Correspondence to Dr Charles Miller, Gastroenterology, University College Hospital London, London, UK; charles.miller{at}nhs.net
View Full Text

Citation

Miller C, Kwok H, Harrow P, et al
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab

Publication history

  • Received May 10, 2021
  • Accepted October 26, 2021
  • First published January 7, 2022.
Online issue publication 
October 18, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.